Literature DB >> 12353063

Venous thromboembolism in von Willebrand disease.

P M Mannucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12353063

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  26 in total

Review 1.  Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

Review 2.  Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

Authors:  A Girolami; F Tezza; M Scapin; S Vettore; A Casonato
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

3.  Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.

Authors:  Gianna Franca Rivolta; Caterina Di Perna; Massimo Franchini; Federica Riccardi; Luigi Ippolito; Maria Lombardi; Annarita Tagliaferri
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

4.  Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).

Authors:  T C Abshire; A B Federici; M T Alvárez; J Bowen; M D Carcao; J Cox Gill; N S Key; P A Kouides; K Kurnik; A E Lail; F W G Leebeek; M Makris; P M Mannucci; R Winikoff; E Berntorp
Journal:  Haemophilia       Date:  2012-07-23       Impact factor: 4.287

5.  Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk.

Authors:  Holleh D Husseinzadeh; Sandra Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.

Authors:  A Kahlon; J Grabell; A Tuttle; D Engen; W Hopman; D Lillicrap; P James
Journal:  Haemophilia       Date:  2013-05-28       Impact factor: 4.287

Review 7.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

Review 8.  Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?

Authors:  Massimo Franchini; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2008-08-14       Impact factor: 2.300

9.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 10.  Prophylaxis of bleeding episodes in patients with von Willebrand's disease.

Authors:  Augusto B Federici
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.